FundingWatcher
Home / Startups / Top health care startups / Health care startups that raised Series A / Health care startups that raised Series A in China

Health care startups that raised Series A in China

Updated 16 Nov 2026

Reset
Health care startups that raised Series A in China
One-time CSV
  • 1,172 funded companies, 725 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-health-care--series-a~china-500a.csv1,172 rows × 18 columns
CompanyCityLast roundAmountDate
Aibo Medical RobotShenzhenSeries A$14.1M2026-10-15
Phil Rivers TechnologyBeijingSeries A$29.6M2026-08-05
Tianhu TechnologyMinhangSeries A$29.0M2026-07-13
Prime LifescienceHangzhouSeries A$14.7M2026-06-30
Lingtai Krypton BiotechnologyShuangliuSeries A$13.7M2026-06-26
Artivila TherapeuticsShenzhenSeries A$14.7M2026-06-23
MoleculeMindHaidianSeries A$86.0M2026-06-17
Haimai MedicalSuzhouSeries A$14.3M2026-06-12

8 rows of the CSV in 5 of its 18 columns.

1,172
Startups
$11.1B
Total raised
163
Funded in the last 12 months
$1.5B
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

30 of 1,172
30 rows
Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
Aibo Medical Robot Aibo Medical Robot researches and develops robots for vascular interventional surgery. Hardware Shenzhen Series A $14.1M 2026-10-15 $33.0M Lenovo Capital and Incubator Group (LCIG), CDH Investments, Long Hill Capital +2 2020
Phil Rivers Technology Phil Rivers Technology provides AI solutions for pharmaceutical research and development. Artificial intelligence Beijing Series A $29.6M 2026-08-05 $57.3M Insight Capital 51 to 100 2015
Tianhu Technology Tianhu Technology uses computational chemistry and artificial intelligence to design new drug molecules. Artificial intelligence Minhang Series A $29.0M 2026-07-13 $54.2M Qiming Venture Partners, GSR United Capital, 3E Bioventures 11 to 50 2021
Prime Lifescience Prime Lifescience develops a big data platform for life sciences research and analysis. Biotech Hangzhou Series A $14.7M 2026-06-30 $44.5M Qiming Venture Partners, Qiji Investment, Ennovation Ventures 11 to 50 2021
Lingtai Krypton Biotechnology Lingtai Krypton Biotechnology develops lncRNA drugs to treat human diseases. Biotech Shuangliu Series A $13.7M 2026-06-26 $13.7M Legend Capital, Guosheng Capital, Firefly Haoyue 11 to 50 2021
Artivila Therapeutics Artivila Therapeutics uses artificial intelligence to discover new pharmaceutical drugs for patients. Artificial intelligence Shenzhen Series A $14.7M 2026-06-23 $53.3M Highlight Capital, Med-Fine Capital, Hike Capital +2 11 to 50 2018
MoleculeMind MoleculeMind combines artificial intelligence with biotechnology to develop new drugs and biological solutions. Artificial intelligence Haidian Series A $86.0M 2026-06-17 $114.6M Shenzhen Capital Group, Lenovo Capital and Incubator Group (LCIG), Sense Capital 51 to 100 2022
Haimai Medical Haimai Medical develops tissue engineering and regenerative medicine technologies. Health care Suzhou Series A $14.3M 2026-06-12 $14.3M IDG Capital, Shanghai Biomedical Industrial Equity Investment Fund, Tahoe Venture +1 51 to 100 2021
Degron Therapeutics Degron Therapeutics discovers molecular glue degraders for cancer treatment. Biotech Shanghai Series A $40.0M 2026-05-14 $94.0M Baidu Ventures, BioVenture, New Alliance Capital +2 101 to 250 2021
Shanmu SHANMU Shanmu develops micro medical robots using digital microfluidic chipsets and artificial intelligence algorithms. Artificial intelligence Shenzhen Series A $14.7M 2026-05-06 $16.0M QF Capital, Hofan Venture, Wanwu Capital +1 1 to 10 2020
Neurodome Neurodome manufactures non-invasive deep brain nerve modulation technology and products. Biotech Xian Shi Series A $14.5M 2026-03-12 $14.5M Shunwei Capital, Frees Fund, Oriza Holdings +2 11 to 50 2019
iCamumo iCamumo develops off-the-shelf, general-purpose cell therapies using iPSCs. Biotech Suzhou Series A $14.4M 2026-03-09 $75.2M Delian Capital, West Lake Science and Technology Direct Investment Fund, Zhiyi Investment 51 to 100 2021
Xingsai Bio Xingsai Bio develops single-cell analysis instruments and related reagents and consumables. Biotech Qingdao Shi Series A $14.4M 2026-01-19 $28.3M Hengxu Capital, Haitang Fund, Neovision Capital +1 51 to 100 2014
Dishi Medical Dishi Medical manufactures ophthalmic medical devices and micro-assisted robots supported by biotechnology. Biotech Hangzhou Series A $13.7M 2026-01-19 $13.7M Hillhouse Investment, Fortune Venture Capital, Linear Capital +1 11 to 50 2021
Huixin Medical Valley Huixin Medical Valley develops cell therapies for neurological illnesses as a biopharmaceutical company. Biotech Changping Series A $14.3M 2026-01-07 $14.3M Green Pine Capital Partners, Jiuzhi Ziben, Beijing Venture Capital 51 to 100 2021
Allink Biotherapeutics Allink Biotherapeutics develops multi-specific antibodies for treating cancer and immune disorders. Biotech Shanghai Series A $47.0M 2025-12-16 $89.0M Legend Capital, Gaorong Capital, BioVenture +2 11 to 50 2023
Junji Gene Junji Gene provides intelligent gene synthesis labs and localizes raw materials for diagnostic kits. Artificial intelligence Suzhou Series A $14.2M 2025-12-15 $14.2M Dongfang Jiafu 51 to 100 2021
Ningkang Ruizhu Ningkang Ruizhu develops targeted drugs. Biotech Zhuhai Series A $14.1M 2025-12-05 $25.6M GF Qianhe Investment, RiverHead Capital, Hanne Capital +1 11 to 50 2019
Yihe Pharmaceutical Yihe Pharmaceutical develops inhalation preparations and inhalation devices. Health care Ningbo Series A $6.9M 2025-11-27 $13.8M Ruihe Capital, Shining Capital 51 to 100 2020
Kunshi Biotechnology Kunshi Biotechnology develops drugs with an emphasis on solid tumor cells. Biotech Suzhou Series A $7.0M 2025-11-20 $7.0M Deshi Capital 51 to 100 2021
Brise Pharma Brise Pharma provides scientific research and technical services in the pharmaceutical field. Biotech Shanghai Series A $28.1M 2025-11-11 $228.3M Qiming Venture Partners, Sherpa Healthcare Partners, BioTrack Capital +1 11 to 50 2021
PulseCare PulseCare is a medtech company that makes medical devices for cardiac and pan-vascular treatment. Health care Shenzhen Series A $14.0M 2025-11-06 $28.1M Delian Capital, Tasly Capital, Tianfeng Capital 11 to 50 2021
Xijian Technology Xijian Technology industrializes human biomechanics imaging technology. Health care Daxing Series A $1.4M 2025-07-16 $1.4M Everbright ReinFore, Yuanhui Chuangyi, Yizhuang Venture Capital 11 to 50 2021
Shandong Bona Group Shandong Bona Group develops material separation, extraction, and purification technologies as a biotechnology company. Biotech Jinan Series A $13.8M 2024-07-24 $13.8M Lucion, Jinan Jigao Finance 51 to 100 2012
AnDiConBio AnDiConBio develops respiratory anti-infection drugs for pain and respiratory conditions. Biotech Jiaxing Series A $27.6M 2024-04-29 $27.6M Cowin Capital, Wenzhou Capital, Huajin Avenue Investment 11 to 50 2018
Scitech pharma Scitech pharma uses AI to design and develop drugs focused on patient demand and clinical value. Biotech Shunyi Series A $13.8M 2024-04-26 Lichen Capital, Zhizhong Investment 251 to 500 2015
Boyuan Biotechnology Boyuan Biotechnology offers a one-stop service platform for animal and plant functional gene research. Biotech Wuhan Series A $1.4M 2024-01-05 Addor Capital 101 to 250 2011
Changsha Morning Shine Changsha Morning Shine is a pharmaceutical company offering CDMO, chemical drug, and biotechnology services. Biotech Changshan Series A $14.1M 2023-12-14 $14.1M BioVenture, Jolmo Capital, Sunz Fund 2019
Hanhong Technology Hanhong Technology is a biomedicine firm focused on drug research, synthetic biology, and pharmaceutical intermediates. Biotech Xuhui Series A $13.9M 2023-12-11 WisdoMont Asset Management, Jinshuihu Fund 101 to 250 2003
Hicicare Hicicare develops pan-vascular interventional medical devices. Health care Guangdong Series A $14.0M 2023-12-07 $14.0M Chiron Ventures, Qiaojing Capital, Zhejiang Innovation Development Capital +2 2019

Table 1. Health care startups that raised Series A in China: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 1,172.

Largest rounds

Last 12 months
10 rows
# Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
1 MoleculeMind MoleculeMind combines artificial intelligence with biotechnology to develop new drugs and biological solutions. Artificial intelligence Haidian Series A $86.0M 2026-06-17 $114.6M Shenzhen Capital Group, Lenovo Capital and Incubator Group (LCIG), Sense Capital 51 to 100 2022
2 Allink Biotherapeutics Allink Biotherapeutics develops multi-specific antibodies for treating cancer and immune disorders. Biotech Shanghai Series A $47.0M 2025-12-16 $89.0M Legend Capital, Gaorong Capital, BioVenture +2 11 to 50 2023
3 Degron Therapeutics Degron Therapeutics discovers molecular glue degraders for cancer treatment. Biotech Shanghai Series A $40.0M 2026-05-14 $94.0M Baidu Ventures, BioVenture, New Alliance Capital +2 101 to 250 2021
4 Phil Rivers Technology Phil Rivers Technology provides AI solutions for pharmaceutical research and development. Artificial intelligence Beijing Series A $29.6M 2026-08-05 $57.3M Insight Capital 51 to 100 2015
5 Tianhu Technology Tianhu Technology uses computational chemistry and artificial intelligence to design new drug molecules. Artificial intelligence Minhang Series A $29.0M 2026-07-13 $54.2M Qiming Venture Partners, GSR United Capital, 3E Bioventures 11 to 50 2021
6 Artivila Therapeutics Artivila Therapeutics uses artificial intelligence to discover new pharmaceutical drugs for patients. Artificial intelligence Shenzhen Series A $14.7M 2026-06-23 $53.3M Highlight Capital, Med-Fine Capital, Hike Capital +2 11 to 50 2018
7 Prime Lifescience Prime Lifescience develops a big data platform for life sciences research and analysis. Biotech Hangzhou Series A $14.7M 2026-06-30 $44.5M Qiming Venture Partners, Qiji Investment, Ennovation Ventures 11 to 50 2021
8 Shanmu SHANMU Shanmu develops micro medical robots using digital microfluidic chipsets and artificial intelligence algorithms. Artificial intelligence Shenzhen Series A $14.7M 2026-05-06 $16.0M QF Capital, Hofan Venture, Wanwu Capital +1 1 to 10 2020
9 Neurodome Neurodome manufactures non-invasive deep brain nerve modulation technology and products. Biotech Xian Shi Series A $14.5M 2026-03-12 $14.5M Shunwei Capital, Frees Fund, Oriza Holdings +2 11 to 50 2019
10 iCamumo iCamumo develops off-the-shelf, general-purpose cell therapies using iPSCs. Biotech Suzhou Series A $14.4M 2026-03-09 $75.2M Delian Capital, West Lake Science and Technology Direct Investment Fund, Zhiyi Investment 51 to 100 2021

Table 2. Health care startups that raised Series A in China: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 BioVenture Venture capital firm Suzhou, China 8 1% 2 Degron Therapeutics, Allink Biotherapeutics
2 Qiming Venture Partners Venture capital firm Shanghai, China 7 1% 2 Tianhu Technology, Prime Lifescience
3 Shenzhen Capital Group Venture capital firm Nanshan, China 7 1% 1 MoleculeMind
4 Lenovo Capital and Incubator Group (LCIG) Venture capital firm Beijing, China 5 0% 2 Aibo Medical Robot, MoleculeMind
5 ZhenFund Entrepreneurship program Beijing, China 5 0%
6 Matrix Partners China Venture capital firm Beijing, China 5 0%
7 CDH Investments Private equity firm Kowloon City, Hong Kong 4 0% 1 Aibo Medical Robot
8 Frees Fund Venture capital firm Beijing, China 4 0% 1 Neurodome
9 Pan-Lin Capital Venture capital firm Shanghai, China 4 0%
10 Taiyu Investment Venture capital firm Beijing, China 4 0%
11 Med-Fine Capital Venture capital firm Shanghai, China 3 0% 2 Artivila Therapeutics, Degron Therapeutics
12 IDG Capital Private equity firm Beijing, China 3 0% 1 Haimai Medical
13 Baidu Ventures Venture capital firm Beijing, China 3 0% 1 Degron Therapeutics
14 New Alliance Capital Private equity firm Shanghai, China 3 0% 1 Degron Therapeutics
15 QF Capital Private equity firm Shenzhen, China 3 0% 1 Shanmu SHANMU

Table 3. Health care startups that raised Series A in China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Biotech 397 34% $6.2B
Software 116 10% $1.1B
Hardware 57 5% $271.4M
Artificial intelligence 53 5% $807.3M
Commerce 28 2% $55.2M
Fintech 18 2% $1.3B
Education 18 2% $58.1M
Energy 6 1% $60.6M
Cybersecurity 2 0%

Table 4. Health care startups that raised Series A in China by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series A 1,172 100% $4.4M

Table 5. Health care startups that raised Series A in China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Beijing 163 14%
Shanghai 149 13%
Shenzhen 110 9%
Hangzhou 99 8%
Suzhou 72 6%
Haidian 48 4%
Guangzhou 41 3%
Nanjing 36 3%
Chengdu 36 3%
Wuhan 18 2%
Xuhui 17 1%
Minhang 17 1%

Table 6. Health care startups that raised Series A in China by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
November 2026 3 2% $50.0M
October 2026 10 6% $105.3M
September 2026 3 2% $59.6M
August 2026 11 7% $138.6M
July 2026 11 7% $152.0M
June 2026 12 7% $232.0M
May 2026 16 10% $212.1M
April 2026 6 4% $52.6M
March 2026 10 6% $84.1M
February 2026 9 6% $14.4M
January 2026 32 20% $140.5M
December 2025 25 15% $189.5M
November 2025 15 9% $113.8M

Table 7. Health care startups that raised Series A in China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 123 10% $1.2B
2025 183 16% $1.4B
2024 96 8% $568.3M
2023 112 10% $772.0M
2022 94 8% $1.1B
2021 70 6% $1.1B

Table 8. Health care startups that raised Series A in China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 40 3%
2020 to 2022 269 23%
2015 to 2019 416 36%
2010 to 2014 255 22%
Before 2010 168 15%

Table 9. Health care startups that raised Series A in China by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 99 11%
11 to 50 375 41%
51 to 100 188 21%
101 to 250 130 14%
251 to 500 67 7%
501 to 1,000 24 3%
1,001 to 5,000 16 2%
5,001 to 10,000 2 0%
10,001 or more 6 1%

Table 10. Health care startups that raised Series A in China by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many health care startups in China whose last round is Series A are on the list?
1,172, in the file dated 16 November 2026. 163 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 1,172 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Health care startups that raised Series A in China: 1,172 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $349 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Health care at other stages in China

Other sectors that raised Series A in China

Cite: FundingWatcher, 1,172 health care companies in China whose most recent round is Series A, 16 November 2026. https://fundingwatcher.com/startups/health-care/series-a/china-500a/